Evidence map›Paper›PMID 30800222›Full record

ArticleOncotarget2019

The correlation of p22

Masayuki Kobayashi, Ryoko Saito, Yasuhiro Miki, Ren Nanamiya, Chihiro Inoue, Jiro Abe, Ikuro Sato, Yoshinori Okada, Hironobu Sasano

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Masayuki KobayashiDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Ryoko SaitoDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Yasuhiro MikiDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Ren NanamiyaDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Chihiro InoueDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Jiro AbeDepartment of Thoracic Surgery, Miyagi Cancer Center, Miyagi, Japan.
Ikuro SatoDepartment of Pathology, Miyagi Cancer Center, Miyagi, Japan.
Yoshinori OkadaDepartment of Thoracic Surgery, Tohoku University Hospital, Miyagi, Japan.
Hironobu SasanoDepartment of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Tohoku University · JPMiyagi Prefectural Hospital Organization · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnhancing the chemosensitivity in the patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant lung adenocarcinoma (LUAD) is pivotal in achieving their successful therapeutic outcome. We aimed to explore the mechanisms regarding the development of therapeutic resistance to chemotherapy in EGFR-TKI resistant LUAD. Methods: Microarray analysis lead to potential involvement of p22

resultsp22

conclusionsThe analysis of p22

Indexed as

chemoresistanceEGFR-TKI resistanceEMTHIF-1αp22phox

Identifiers

PMID30800222
PMCPMC6383684
OpenAlexW2912921222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.